Atopic Dermatitis MedDRA version: 21.1 Level: LLT Classification code 10003639 Term: Atopic dermatitis System Organ Class: 100000004858
Conditions
Sponsors
UCB Biopharma SRL
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Part A: -Participant must be 18 to 55 years of age inclusive at the time of signing the informed consent form (ICF) -Participant must be overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring -Participant has a body mass index (BMI) within the range 18 to 30 kg/m^2 (inclusive) -Participant can be male or female -A male participant must agree to use contraception during the Treatment Period and for at least 90 days after the final dose of investigational medicinal product (IMP), and refrain from donating sperm during this period -A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least 1 of the following conditions applies: i) Not a woman of childbearing potential (WOCBP) OR ii) A WOCBP who agrees to follow the contraceptive guidance during the treatment period and for at least 90 days after the final dose of IMP Part B: -Participant must be 18 to 65 years of age inclusive at the time of signing the ICF -Participant has a documented history of moderate or severe AtD that has been present for at least 12 months prior to initiating the study (signing of the ICF) and with: • validated Investigator Global Assessment (vIGA) score =3 at Screening (Visit 1) and Baseline (Visit 2) • Eczema Area and Severity Index (EASI) score of =14 at Screening (Visit 1) and =16 at Baseline (Visit 2) • Pruritus Numerical Rating Scale (NRS) score = 3 at Screening (Visit 1) and Baseline (Visit 2) • =10% body surface area (BSA) of AtD involvement at Screening (Visit 1) and Baseline (Visit 2) • Either documented recent history (within 6 months before the Screening Visit) of inadequate response to treatment with topical medications (regular use of topical corticosteroids [TCS] or topical calcineurin inhibitors [TCIs]) or when topical treatments are confirmed to be otherwise medically inadvisable (eg, because of important side effects or safety risks). Inadequate response is defined as failure to achieve and maintain remission or low disease remission or a low disease activity state (vIGA 0=clear to vIGA 2=mild) despite treatment with a daily regimen of TCS of medium to higher potency (±TCI as appropriate), applied for at least 4 weeks or for the maximum duration recommended by the product prescribing information (eg, 2 weeks for high potency TCS), whichever is shorter. -Participant has a body mass index (BMI) within the range 18 to 32 kg/m^2 (inclusive) -Participant can be male or female -A male participant must agree to use contraception during the Treatment Period and for at least 60 days after the final dose of IMP, and refrain from donating sperm during this period -A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least 1 of the following conditions applies: i) Not a woman of childbearing potential (WOCBP) OR ii) A WOCBP who agrees to follow the contraceptive guidance during the treatment period and for at least 60 days after the final dose of IMP Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 135 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 7
Exclusion criteria
Exclusion criteria: Part A: -Participant has a known hypersensitivity to any components of the investigational medicinal product (IMP) or other biologic drugs as stated in this protocol -Participant has a significant allergy to humanized monoclonal antibodies (mAbs) -Participant has clinically significant multiple or severe drug allergies, intolerance to topical corticosteroids, or severe posttreatment hypersensitivity reactions -Participant has abnormal blood pressure (BP; outside the normal range) in a supine position after 5 minutes rest - Participant has alanine aminotransferase (ALT), aspartate aminotransferase (AST), or alkaline phosphatase (ALP) >1.0x upper limit of normal (ULN) -Participant has a recent history or currently active clinically-significant bacterial, fungal, endoparasite, or viral (including hospitalization for coronavirus disease 2019 (COVID-19)) infection (within 6 months of the Screening Visit) -Participant has a history of inflammatory bowel disease (includes Crohn’s disease and ulcerative colitis) -Participant has a history of diabetes -Participant has a corrected QT interval (QTc) >450 msec -Participant has received any prescription or nonprescription medicines, including over the counter remedies and herbal and dietary supplements (other than vitamins within recommended daily dose limits), within 14 days (or 5 half-lives of the respective drug, whichever is longer) prior to the Baseline Visit, other than contraceptives (oral, implants, or intrauterine devices) or occasional use of analgesics, such as paracetamol (acetaminophen, with or without caffeine, with a maximal dose of 4 g/day and 10 g/14 days) -Participant has received Bacillus Calmette-Guerin vaccinations within 1 year prior to the Baseline Visit or within 90 days after the final dose of IMP -Participant has been treated with biologic agents (such as mAbs, including marketed drugs) within 3 months or 5 half-lives (whichever is longer) prior to the Baseline Visit -Participant has participated in another study of an IMP within the previous 90 days or 5 half-lives of the IMP (whichever longer), or is currently participating in another study of an IMP -Participant has sensitivity to heparin or heparin-induced thrombocytopenia Part B: -Participant has a known hypersensitivity to any components of the IMP or other biologic drugs as stated in this protocol -Participant has significant allergies to humanized mAbs -Participant has clinically significant multiple or severe drug allergies, or severe posttreatment hypersensitivity reactions (including, but not limited to, erythema multiforme major, linear immunoglobulin A (IgA) dermatosis, toxic epidermal necrolysis, and exfoliative dermatitis) -Participant has abnormal BP (outside the normal range) in a supine position after 5 minutes rest - Participant has ALT, AST, or ALP >1.5xULN -Participant has a recent history of or clinically active clinically-significant, as judged by the Investigator, bacterial, fungal, endoparasite, or viral (or any history of hospitalization for COVID-19) infection (within 6 months of the Screening Visit) -Participant has a history of inflammatory bowel disease (includes Crohn’s disease and ulcerative colitis) -Participant has a history of diabetes that is not well controlled with diet -Participant has a mean QTc >450 msec for male study participants or >470 msec for female study participants. -Participant has received any prescription or nonprescription medicines, including over the counter remed
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: -Investigation of safety and tolerability of single-ascending doses of UCB9741 administered by intravenous (iv) infusion or subcutaneous (sc) injection to healthy study participants -Investigation of safety and tolerability of UCB9741 following repeat-dosing at a single dose level in study participants with with atopic dermatitis (AtD) -Investigation of a primary clinical outcome in study participants with AtD after administration of UCB9741 by iv infusion ;Secondary Objective: -Investigation of pharmacokinetic parameters of UCB9741 administered as single-ascending doses (intravenous and subcutaneous) in healthy study participants -Investigation of other clinical outcomes in study participants with AtD after administration of UCB9741 by iv infusion -Investigation of pharmacokinetic parameters of UCB9741 following repeat-dosing at a single dose level in study participants with AtD ;Primary end point(s): 1. Incidents of treatment-emergent adverse events (TEAEs) during Part A 2. Incidents of treatment-emergent serious adverse events (TESAEs) during Part A 3. Incidents of TEAEs during Part B 4. Incidents of TESAEs during Part B 5. =75% improvement vs Baseline in Eczema Area and Severity Index (EASI75) score during Part B ;Timepoint(s) of evaluation of this end point: 1-2: From Baseline up to the End of Study Visit (Week 12) 3-4: From Baseline up to the End of Study Visit (Week 18) 5: Baseline, Week 12 | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): 1. Cmax from Baseline through the End of Study (EoT) Visit of Part A 2. Tmax from Baseline through the End of Study (EoT) Visit of Part A 3. AUC(0-t) from Baseline through the End of Study (EoT) Visit of Part A 4. AUC from Baseline through the End of Study (EoT) Visit of Part A 5. F% from Baseline through the End of Study (EoT) Visit of Part A 6. Percent change from Baseline in the Eczema Area and Severity Index (EASI) score at Week 12 of Part B 7. =50% improvement vs Baseline in EASI score (EASI50) at Week 12 during Part B 8. =90% improvement vs Baseline in EASI score (EASI90) at Week 12 during Part B 9. Cmax after the final dose of Part B 10. Tmax after the final dose of Part B 11. AUCtau at Week 12 of Part B;Timepoint(s) of evaluation of this end point: 1- 5: From Baseline through the End of Study Visit (Week 12) 6 - 8: Baseline, Week 12 9 - 11: Week 12 | — |
Countries
Belgium, Bulgaria, Germany, Netherlands, Poland, Spain, United Kingdom
Contacts
Public ContactClin Trial Reg & Results Disclosure
UCB BIOSCIENCES GmbH
Outcome results
None listed